一药多用，减重15%还能控血压、降血脂、降尿酸！创新药物为中国肥胖患者带来全新治疗选择

Core Viewpoint - The article discusses the rising global obesity rates and the emergence of innovative weight loss drugs, particularly focusing on Mazdutide, a dual agonist of GLP-1R and GCGR, which has shown significant weight loss and metabolic improvement in clinical trials [7][15]. Group 1: Clinical Trial Results - The GLORY-1 trial is a randomized, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of Mazdutide in Chinese adults with obesity [8]. - The study included 610 participants with a BMI of ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity, with an average baseline weight of 87.2 kg and BMI of 31.1 kg [8]. - At 32 weeks, the Mazdutide 4 mg and 6 mg groups showed weight reductions of 10.97% and 13.38%, respectively, compared to a 0.24% reduction in the placebo group [9]. - At 48 weeks, the weight reductions were 12.05% for the 4 mg group, 14.84% for the 6 mg group, and 0.47% for the placebo group [10]. Group 2: Efficacy in Weight Loss - The proportion of patients achieving weight loss of ≥5% at 32 weeks was 76.3% for the 4 mg group, 84% for the 6 mg group, and 10.9% for the placebo group [11]. - At 48 weeks, these proportions were 73.5%, 82.8%, and 11.5%, respectively, with ≥10% weight loss achieved by 55.2% and 67.9% in the Mazdutide groups compared to 2.9% in the placebo group [11]. Group 3: Waist Circumference and Metabolic Benefits - At 48 weeks, waist circumference decreased by 9.48 cm in the 4 mg group, 10.96 cm in the 6 mg group, and 1.48 cm in the placebo group, indicating significant improvement in the Mazdutide groups [12]. - The study also monitored cardiovascular health, showing significant benefits from Mazdutide, including reductions in systolic blood pressure (6.75 mmHg), triglycerides (0.52 mmol/L), total cholesterol (0.45 mmol/L), LDL-C (0.31 mmol/L), serum uric acid (50.75 μmol/L), and ALT (10.00 U/L) at 48 weeks [13]. Group 4: Safety Profile - Common adverse effects of Mazdutide were mild to moderate gastrointestinal discomfort, with an overall good and manageable safety profile [14]. Group 5: Future of GLP-1/GCGR Agonists - The development of GLP-1/GCGR dual receptor agonists is progressing, with 11 drugs in the pipeline globally, including one that has submitted for market approval and five in phase 2-3 clinical trials [15][16].